Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuvo Research Announces Scientific Presentation at the Annual Meeting of AAI

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
Data evaluating WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice.

Nuvo Research Inc. has announced that researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI and Nuvo presented scientific data related to WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice at the 100th Annual Meeting of The American Association of Immunologists (AAI) in Honolulu, Hawaii, U.S.

Compared to the placebo group, animals treated with WF10 showed a reduction of the degree of symptoms. Based on these results, the investigators concluded that WF10 may present a novel therapeutic approach for patients suffering from rheumatoid arthritis and other inflammatory autoimmune diseases.

Rheumatoid arthritis is a complex chronic autoimmune disease and the most common inflammatory disorder of joints leading to cartilage destruction, bone erosion and deformation of joints.

The initializing causes of rheumatoid arthritis are not fully understood and thus there can be no guarantee that the results observed in this animal model will be reproducible in humans.

"This joint poster presentation is a result of the deep and fruitful cooperation between Nuvo and the prestigious Fraunhofer Institute in Leipzig, Germany," said Dr. Henrich Guntermann, Nuvo's President, Europe and Immunology Group.

Dr. Guntermann continued, "With our partners in Leipzig and supported by funding from the Development Bank of Saxony (SAB) and the European Fund for Regional Development (EFRE), we are currently working on multiple research and development projects to further explore WF10's full potential."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nuvo Research Announces Collaboration to Develop Topical Dermatology Products
Company will utilize its proprietary MMPE technology to formulate topical dermatology products.
Saturday, April 26, 2014
Nuvo Research Announces 2013 Fourth Quarter & Year-End Results
Company will commence a Phase 2 study of WF10 with results expected in Q4 2014.
Friday, March 07, 2014
Nuvo Research® and NovaMedica Sign Agreement to Market Pennsaid® in Russia
Sales of Pennsaid 1.5% in Russia to begin in 2015.
Monday, December 23, 2013
Nuvo Granted U.S. Patent for Using WF10
New derivative formulations for the treatment of Allergic Rhinitis and Allergic Asthma.
Thursday, May 16, 2013
Nuvo Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%
Patent applications currently pending in Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan and Mexico.
Tuesday, May 14, 2013
Nuvo Research Announces New Listing of Synera® Patent in FDA Orange Book
The Synera Patent expiry date is July 7, 2020.
Thursday, December 27, 2012
Nuvo Research Receives €4.4 Million Additional Funding to Develop WF10
Total cost of the development program is estimated to be €6.3 million.
Thursday, December 27, 2012
Nuvo Research Announces 2012 Second Quarter Results
Company receives notice of a positive opinion for the approval of Pliaglis.
Tuesday, August 07, 2012
Nuvo Research to Receive US$6.0 Million of Milestone Payments from Pliaglis® E.U. Approvals
Nuvo to launch Pliaglis in the E.U. and other territories in the first half of 2013.
Friday, July 20, 2012
Nuvo Research Provides PENNSAID® Commercial Update
U.S. licensee resumes distribution of PENNSAID sample bottles.
Monday, June 18, 2012
Pliaglis Receives Positive Opinion from the BfArM in the E.U.
Enters national licensing phase in 17 E.U. countries.
Tuesday, May 08, 2012
Nuvo Research Announces 2012 First Quarter Results
U.S. prescriptions of Pennsaid continued to grow quarter-over-quarter.
Thursday, May 03, 2012
Nuvo Research Announces Management Change
Stephen L. Lemieux to become Vice President and Chief Financial Officer of Nuvo Research.
Monday, February 13, 2012
Nuvo Research U.S. Awarded US$1.3 Million in Research Grants
The grants were awarded for 2009 and 2010 research programs relating to topical and transdermal formulations.
Thursday, November 11, 2010
Nuvo Research Announces Positive Top-Line WF10 Phase II Trial Results
European Phase II clinical trial evaluating WF10 as a treatment for severe allergic rhinitis meets its primary endpoint.
Tuesday, November 09, 2010
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Self-Assembling, Biomimetic Membranes May Aid Water Filtration
A synthetic membrane that self assembles and is easily produced may lead to better gas separation, water purification, drug delivery and DNA recognition, according to an international team of researchers.
Researchers Discover Immune System’s 'Trojan Horse'
Oxford University researchers have found that human cells use viruses as Trojan horses, transporting a messenger that encourages the immune system to fight the very virus that carries it.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
How Cholesterol Leads to Clogged Arteries
A new study shows that when immune cells called neutrophils are exposed to cholesterol crystals, they release large extracellular web-like structures that trigger the production of inflammatory molecules linked to artherosclerosis.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Ultrafast DNA Diagnostics
New technology developed by UC Berkeley bioengineers promises to make a workhorse lab tool cheaper, more portable and many times faster by accelerating the heating and cooling of genetic samples with the switch of a light.
Researchers Discover New Type of Mycovirus
Virus infects the fungus Aspergillus fumigatus, which can cause the human disease aspergillosis.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!